Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1516 results for patients and public

  1. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

    Technology appraisal guidance
    Published
    26 February 2025
    View recommendations

    Sections for TA1044

  2. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (HTG99)

    Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.

    HealthTech guidance
    Published
    22 February 2006
    View recommendations

    Sections for HTG99

  3. Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)

    Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.

    HealthTech guidance
    Published
    26 April 2006
    View recommendations

    Sections for HTG110

  4. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

    NICE guideline
    Published
    11 March 2020
    View recommendations

    Sections for NG155

  5. Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.  Find out  what special arrangements mean on the NICE website .

    Give patients clear information to support shared decision making , including NICE's information for the public . Ensure...

    Research recommendation
    Published
    10 August 2020

  6. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA692

  7. The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI raises no major safety concerns other than those associated with the TAVI procedure. However, the evidence on efficacy for preventing TAVI-related stroke is inconclusive. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Inform the clinical governance leads in their NHS trusts. Ensure that patients and their carers understand the procedure's safety and...

    Research recommendation
    Published
    15 November 2019

  8. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)

    Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over.

    Technology appraisal guidance
    Published
    13 August 2025
    View recommendations

    Sections for TA1088

  9. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

    Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

    Evidence summary
    Published
    14 February 2017

  10. Alpha-Stim AID for anxiety disorders (HTG570)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

    HealthTech guidance
    Published
    8 March 2021
    View recommendations

    Sections for HTG570

  11. Lower limb deep vein valve reconstruction for chronic deep venous incompetence (HTG141)

    Evidence-based recommendations on lower limb deep vein valve reconstruction for chronic deep venous incompetence. This involves restructuring valves in the deep veins of the legs by various surgical techniques, such as using stitches to repair the valve.

    HealthTech guidance
    Published
    23 May 2007
    View recommendations

    Sections for HTG141

  12. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Inform the clinical governance leads in their NHS trusts. Ensure that patients and their carers understand the uncertainty about the...

    Research recommendation
    Published
    15 November 2019

  13. Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  20 May 2026

    Health technology evaluations
    In development

  14. Leukapheresis for inflammatory bowel disease (HTG75)

    Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.

    HealthTech guidance
    Published
    22 June 2005
    View recommendations

    Sections for HTG75

  15. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute iliofemoral DVT the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Inform the clinical governance leads in their NHS trusts. Ensure that patients understand the procedure's safety and efficacy, as well...

    Research recommendation
    Published
    27 May 2020